Publications

MSc Thesis:

• Early Virological Response of the First Line Combination Therapy (Pegylated Interferon Alfa 2a and Ribavirin) in Iraqi Chronic Hepatitis C Patients and Their Adverse Effects

PhD Thesis:

• Potential role of orlistat and telmisartan in patients with sub-clinical non-alcoholic fatty liver disease

Journal Papers

• Wasta Esmail V, Al-Shamma K, Hussein H, 2012. Early virological response of the first line combination therapy (pegylated interferone a-2a and ribavirin) in Iraqi chronic hepatitis C patients and their psychological adverse effects. Global Journal of Medical Research, 12 (11).

• Wasta Esmail V, Hamid D, Ratha R, 2016. Prevalence of flu-like syndrome among chronic hepatitis C infected patients treated with the first line combination therapy (pegylated interferon a-2a and ribavirin). International Journal of Development Research, 6 (2): 6605- 8.

• Wasta Esmail V, Hamid D, Ratha R, 2016. Pegylated interferon a-2a therapy and occurrence of sinus tachycardia in chronic hepatitis C infected patients. Donnish Journal of Medicine and Medical Sciences, 3: 1-5.

• Al- Nimer M, Wasta Esmail V, Mohammad M, 2019. Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. Electronic Journal of General Medicine, 16 (3); em142.

• Al- Nimer M, Wasta Esmail V, Hamid D, Mohammad M, 2020. A Preliminary report about the detection of ventricular repolarisation in patients with non-alcoholic fatty liver disease. Journal of Taibah University Medical Sciences, 15(4); 284-91.

• Wasta Esmail V, Mohammad M, Al- Nimer M, 2021. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab Journal of Gastroenterology, 22(2021); 1-5.

• Esmail VAW, Al-Nimer MSM, Mohammed MO. Effects of orlistat or telmisartan on the serum free fatty acids in non-alcoholic fatty liver disease patients: an open-labeled randomized controlled study. Turk J Gastroenterol. 2022;33(5):421-426

• 
  

Conference Papers